Page 337 - Glucose Monitoring Devices
P. 337

Sensor  Dexcom G5  versus  Enlite  Dexcom G5  Guardian 3  iPRO  (Medtronic)  Dexcom  G4Share  Guardian 3  Dexcom G6  Guardian 3  (continued)






                 Hormone  Insulin  Insulin,  Glucagon  Insulin  Insulin  Insulin  Insulin  Insulin  Insulin  Insulin
          2019.dcont’d  device






          July   Infusion  Tandem insulin pump  versus MiniMed  Paradigm Veo  Omnipod (APC  controller with  exercise detection)  670G  Omnipod (MPC)  670G  Tandem t:slim X2  with control IQ  Medtronic 670G 4.0  HCL (AHCL) with  Guardian 3
          and
          May

          between  Intervention  control  versus  HCL versus SAP with  PLGS  Insulin only HCL  versus  insulin þ glucagon  HCL versus CSII with  PLGS  HCL versus CSII    sensor  HCL versus Standard  therapy  HCL versus SAP or  MDI or CSII  HCL versus SAP  Advanced HCL  AHCL versus HCL


          recruiting



          as  studies  Environment  Outpatient  Free living  Inpatient and  outpatient  Outpatient,  inpatient for  clamp  Outpatient  Outpatient  Outpatient  Outpatient  Outpatient  Clinic (part 1)  Camp (part 2)
          listed  Pediatric

          were  Age  (years)  18þ  21e50  25e70  50e75  2e85  2e80     6-10,  65þ  7e75  10e40

          that  (per
          ClinicalTrials.gov  Duration  arm)  12 d  9 h inpatient,  67 h outpatient  22 mo  8e10 wk  2e5d  6mo  8e10 wks  3 mos  36 hr







          on     design  2-way crossover  3-way crossover              Nonrandomized  Segment 1, part  pilot Segment 1  part 2dcrossover
          listed  Study  Randomized  Open label  Clinical trial  Randomized  clinical trial  Single arm  Open-label  Clinical trial  Randomized  Parallel group  Clinical trial  Single arm  Open label  Observational  Free living  Feasibility  Randomized  Parallel group  Adaptive study  crossover  Clinical trial  Single arm  Open label  Clinical trial  1dsingle arm,

          studies                                  studies


          Closed-loop  Title  Closed-loop control  of glucose levels  (artificial pancreas)  for 12 days in adults  with T1D  Three-way  crossover closed-  loop study with xeris  glucagon  Hybrid closed-loop  insulin delivery  system in  hypoglycemia (Aim2)  Using an artificial  pancreas system in  older adult T1D  patients (T1DM AP)  adult  Insulet artificial  pancreas free-living  IDE3  Multicenter trial in  adult and pediatric




          16.1  trial  NCT02846831  NCT03424044  NCT03215914  NCT03353792  and Pediatric  NCT03216460  NCT02748018  NCT03674281  NCT03959423  NCT02776696

          Table  Clinical  ID
   332   333   334   335   336   337   338   339   340   341   342